866-997-4948(US-Canada Toll Free)

Requip (ropinirole) Analysis and Estimates from 2002 to 2020

Published By :

GlobalData

Published Date : Jul 2011

Category :

Therapeutic Area

No. of Pages : 38 Pages


GlobalDatas pharmaceuticals report, Requip (ropinirole) Analysis and Estimates from 2002 to 2020 provides Requip sales estimates for US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2002-2020). The report also includes information on Parkinson's Disease market. This report is built using data and information sourced from GlobalDatas proprietary databases, primary and secondary research using Companys corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts. 

Scope
  • Therapy area profile including patient population for the US, EU5 and Japan (seven major markets)
  • Analysis and review of Requip including historical sales data
  • Qualitative and quantitative assessment of market space
  • Analysis of the trends, drivers and restraints shaping and defining the markets
  • In-depth analysis of Requip including efficacy, safety, pricing, competition and other details which influence its sales potential
  • Detailed sales forecast for 2011-2020 for Requip in each of the seven major markets
Reasons to buy
  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of competition by understanding the changing competitive landscape
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of the drugs performance 
  • Examine the historical sales performance of a drug in seven major markets
  • Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets
Table of content

1 Table of contents
1 Table of contents 2
1.1 List of Tables 3
1.2 List of Figures 4

2 Introduction 5
2.1 Parkinsons Disease 5
2.2 Symptoms of Parkinsons Disease 5
2.3 Diagnosis of Parkinsons Disease 6
2.4 Parkinsons Disease Treatment Strategies 6
2.5 Parkinsons Disease Market 7
2.6 Epidemiology 7
2.7 Parkinsons Disease by Age and Gender 7
2.8 Etiology 7
2.9 GlobalData Report Guidance 8

3 Parkinsons Disease: Market Characterization 9
3.1 Parkinsons Disease Market 9
3.2 Parkinsons Disease Market Forecasts and CAGR 9
3.3 Factors Affecting Parkinsons Disease Market 10
3.3.1 High Prevalence: Parkinsons Disease is the Second Most Frequent Neurodegenerative Disorder 10
3.3.2 Increase in Old Age Population 10
3.3.3 Patent Expiry of Prominent Drugs 10

4 Stages of Parkinsons Disease and Comparison of Treatments 11
4.1 The Hoehn and Yahr Scale 11
4.2 Modified Hoehn and Yahr Scale 11
4.3 The UPDRS 12

5 Staging of Parkinsons Disease 15
5.1 Distribution of Parkinsons Disease Patients by Age Groups 15
5.2 Distribution of Patients by Stages 15

6 Requip 16
6.1 Introduction 16
6.2 Mechanism of Action 16
6.3 Clinical Studies 16
6.3.1 Studies in Patients with Early Parkinson's Disease 16
6.3.2 Studies in Patients with Advanced Parkinson's Disease 17
6.3.3 Study Conducted on Japanese Patients 18
6.4 Approval History of Requip 19
6.5 Factors Affecting Sales of Requip 19
6.5.1 Used in Multiple Regimens 19
6.5.2 Efficacy Profile 19
6.5.3 Launch of Requip XL 20
6.5.4 Patent Expiry of Requip 20
6.5.5 Behavioral Addictions 20
6.6 Drug Evaluation 20
6.6.1 Drug Risk Benefit Score 20
6.6.2 Intensity of Competition 21
6.7 Sales Estimates 22
6.7.1 Target Patient Pool for Parkinsons Disease 22
6.7.2 Dosing 23
6.7.3 Market Penetration 24
6.7.4 Annual Cost of Therapy 24
6.7.5 Sales Estimates of Requip 25

7 Parkinson Disease Market: Appendix 34
7.1 Market Definitions 34
7.2 List of Abberiviations 34
7.3 Research Methodology 34
7.3.1 Coverage 34
7.3.2 Secondary Research 35
7.3.3 Forecasting 35
7.3.4 Number of Patients Approved to take the Drug 35
7.3.5 Net Penetration of Drug 35
7.3.6 Net Annual Dosing 36
7.3.7 Annual Cost of Therapy 36
7.3.8 Primary Research 36
7.3.9 Expert Panels 37
7.4 Drug Sales Estimates Model 37
7.5 Contact Us 37
7.6 Disclaimer 37
7.7 Sources 38

List of Table


Table 1: Clinical Motor and Nonmotor Features of Parkinsons Disease 5
Table 2: Hoehn and Yahr Stages of Parkinsons Disease 11
Table 3: Hoehn and Yahr Stages of Parkinsons Disease 11
Table 4: Four Items, Part 1 of UPDRS 12
Table 5: Thirteen Items, Part 2 of UPDRS 12
Table 6: Fourteen Items, Part 3 of UPDRS 13
Table 7: Fourteen Items, Part 3 of UPDRS 13
Table 8: Distribution of Parkinsons Patients According to Hoehn and Yahr Classification 15
Table 9: Approval History of Requip 19
Table 10: Drug Risk Benefit Score of Requip 20
Table 11: Efficacy Comparison of Requip with other Dopamine Agonists 21
Table 12: Efficacy Comparison of Requip with other Competitors 22
Table 13: Dosing Schedule of Requip for Parkinsons Disease 23
Table 14: Annual Cost of Requip for Parkinsons Disease, 2010 24
Table 15: Requip, Parkinsons Disease, Global, Sales Estimates ($m), 20022020 25
Table 16: Requip, Parkinsons Disease, The US, Sales Estimates ($m), 20022020 26
Table 17: Requip, Parkinsons Disease, The UK, Sales Estimates ($m), 20022020 27
Table 18: Requip, Parkinsons Disease, France, Sales Estimates ($m), 20022020 28
Table 19: Requip, Parkinsons Disease, Germany, Sales Estimates ($m), 20022020 29
Table 20: Requip, Parkinsons Disease, Italy, Sales Estimates ($m), 20022020 30
Table 21: Requip, Parkinsons Disease, Spain, Sales Estimates ($m), 20022020 31
Table 22: Requip, Parkinsons Disease, Japan, Sales Estimates ($m), 20062020 32

List of Chart


Figure 1: Current Pharmacologic Therapies for Parkinsons disease and Their Potential Sites of Action in the CNS 6
Figure 2: The Age-Specific Prevalence Rates of Parkinsons Disease in the Elderly Among Five European Countries, 2003 7
Figure 3: Parkinsons Disease, Global, Market Size Estimates ($bn), 20102020 9
Figure 4: Proportion of Population 60 Years or Older, World, 1950-2050 10
Figure 5: Points Distribution of UPDRS 14
Figure 6: Distribution of Parkinsons Disease Patients by Hoehn & Yahr Classification 15
Figure 7: Drug Model Diagram of Requip in the US, EU and Japan 23
Figure 8: Requip, Parkinsons Disease, Global, Sales Estimates ($m), 20022020 25
Figure 9: Requip, Parkinsons Disease, The US, Sales Estimates ($m), 20022020 26
Figure 10: Requip, Parkinsons Disease, The UK, Sales Estimates ($m), 20022020 27
Figure 11: Requip, Parkinsons Disease, France, Sales Estimates ($m), 20022020 28
Figure 12: Requip, Parkinsons Disease, Germany, Sales Estimates ($m), 20022020 29
Figure 13: Requip, Parkinsons Disease, Italy, Sales Estimates ($m), 20022020 30
Figure 14: Requip, Parkinsons Disease, Spain, Sales Estimates ($m), 20022020 31
Figure 15: Requip, Parkinsons Disease, Japan, Sales Estimates ($m), 20062020 32
Figure 16: Requip, Parkinsons Disease, Global, Sales Distribution by Country (%), 2007 33
Figure 17: Drug Model Diagram 36
Figure 18: Patients Approved for the Drug 36

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *